title: Choosing a better end point for trials of bone-protective agents.
authors: Oncology Institute & Cancer Research Center, Sheba Medical Center, Tel-Hashomer, Israel.
authors: R
authors: R
authors: Leibowitz-Amit
authors: Princess Margaret Cancer Centre, Toronto, Canada.
authors: L
authors: L
authors: Khoja
authors: Princess Margaret Cancer Centre, Toronto, Canada.
authors: I F
authors: IF
authors: Tannock
authors: Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: anthony.joshua@uhn.ca.
authors: A M
authors: AM
authors: Joshua
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary*; D000069448:Denosumab / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology*
chemical_list: D050071:Bone Density Conservation Agents; D000069448:Denosumab